Stockscreener 앱 받기
26.19
1.71%
0.44
시장 영업 전:
26.80
0.61
+2.33%
전일 마감가:
$25.75
열려 있는:
$25.39
하루 거래량:
1.26M
Relative Volume:
1.09
시가총액:
$1.94B
수익:
$193.35M
순이익/손실:
$-177.58M
주가수익비율:
-10.69
EPS:
-2.45
순현금흐름:
$-172.43M
1주 성능:
-1.32%
1개월 성능:
+20.14%
6개월 성능:
+46.15%
1년 성능:
+7.82%
1일 변동 폭
$25.38
$26.28
1주일 범위
$23.57
$26.53
52주 변동 폭
$16.60
$28.47
슈뢰딩거 Stock (SDGR) Company Profile
명칭
Schrodinger Inc
전화
503-299-1150
주소
1540 BROADWAY, NEW YORK, NY
SDGR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
26.19 | 1.94B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
210.08 | 36.39B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
51.28 | 9.87B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
40.98 | 7.46B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
80.20 | 7.21B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.21 | 6.30B | 906.14M | -52.62M | 89.62M | -0.3621 |
슈뢰딩거 Stock (SDGR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-02 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | 재개 | Piper Sandler | Overweight |
| 2022-12-19 | 개시 | Goldman | Neutral |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-10-13 | 개시 | Berenberg | Buy |
| 2021-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | 개시 | Craig Hallum | Buy |
| 2020-11-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-10-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-02 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-02 | 개시 | Jefferies | Hold |
| 2020-03-02 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
슈뢰딩거 주식(SDGR)의 최신 뉴스
3 Momentum Stocks That Could Soar Post-Market Volatility - Investing.com
3 Momentum Stocks That Could Soar Post-Market Volatility - MarketBeat
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - 01net
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger (NASDAQ:SDGR) shareholders are up 29% this past week, but still in the red over the last five years - simplywall.st
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last? - MSN
An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 26% Undervalued - Yahoo Finance
Schrodinger price target raised to $32 from $30 at KeyBanc - TipRanks
Schrodinger’s Karen Akinsanya sells $419,570 in stock By Investing.com - Investing.com South Africa
Schrodinger’s Karen Akinsanya sells $419,570 in stock - Investing.com
Schrodinger issues statement on FDA phasing out animal testing requirement - TipRanks
FDA recent move marks paradigm shift in drug development, boosting Schrödinger (SDGR) and other biotech stocks - Investorsobserver
Schrodinger (SDGR) Backs FDA's Initiative to Cut Animal Testing in Drug Development | SDGR Stock News - GuruFocus
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal T - GuruFocus
Schrödinger backs FDA’s move away from animal testing By Investing.com - Investing.com South Africa
Schrodinger to Launch Predictive Toxicology Tool in H2 - marketscreener.com
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs - 01net
Schrödinger backs FDA’s move away from animal testing - Investing.com Australia
Schrödinger'S Statement Regarding FDA Plan To Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs - MarketScreener
Vanguard Group Inc. Lowers Holdings in Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade) - Seeking Alpha
Schrödinger (SDGR) Reveals Promising Preclinical Data for Cancer Inhibitors - GuruFocus
Schrodinger Settles Lawsuit Over Director Compensations; Shares Up - MarketScreener
Schrödinger (SDGR) Faces Cash Burn Challenges Amid Growth - GuruFocus
Schrodinger settles director pay lawsuit, to reform governance By Investing.com - Investing.com South Africa
Schrodinger settles director pay lawsuit, to reform governance - Investing.com
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements - Benzinga
Schrodinger Stock Hits 52-Week Low at $16.64 Amid Market Challenges - Investing.com
Schrödinger, Inc. (NASDAQ:SDGR) Shares Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Top 5 AI & Digital Biotech Companies (April 2025) - Securities.io
Swiss National Bank Has $2.41 Million Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Schrödinger Finally Embraces AI – Is It a Buy? - Nanalyze
Schrödinger to Present Preclinical Data at AACR Annual Meeting - 01net
Schrödinger to Present at Four Investor Conferences in September - Business Wire
(SDGR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Schrodinger Inc (SDGR) Trading Down 1.72% on Mar 21 - GuruFocus.com
Schrodinger at KeyBanc Forum: Computational Drug Discovery Focus By Investing.com - Investing.com South Africa
Schrodinger at KeyBanc Forum: Computational Drug Discovery Focus - Investing.com India
(SDGR) Proactive Strategies - Stock Traders Daily
Proficio Capital Partners LLC Purchases Shares of 11,285 Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger adds Bridget van Kralingen to board By Investing.com - Investing.com Australia
Schrodinger at Leerink Global: Strategic Growth and Challenges - Investing.com India
Schrodinger appoints Bridget van Kralingen to board By Investing.com - Investing.com Canada
Schrödinger Appoints Bridget van Kralingen To Board - citybiz
Schrodinger appoints Bridget van Kralingen to board - Investing.com
Schrödinger adds Bridget van Kralingen to board - Investing.com India
슈뢰딩거 (SDGR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
슈뢰딩거 주식 (SDGR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
0.05%
2.26%
자본화:
|
볼륨(24시간):